Tovorafenib for young people with worsening Langerhans cell histiocytosis
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age must be between 180 days old and under 22 years when you enroll.
- You must have LCH that can be measured on scans, and it must be progressing, relapsing, or refractory after prior systemic treatment.
- Your diagnosis must be confirmed with tissue pathology showing LCH, and the team will need submitted biopsy/tissue samples for confirmation and gene testing.
- Your tumor must have a specific gene mutation (not just a test that suggests it): CSFR1, ERBB3, or ALK, or RAS/RAF mutations.
- You must be able to take the study medicine by mouth or through a feeding tube, and your blood counts and organ tests must meet safety thresholds.
- You must not have had certain recent treatments (most cancer drugs/clinical trials within 14 days, radiation within 2 weeks) and must not have certain medical conditions (like severe infections or some eye/heart risks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies tovorafenib to treat craniopharyngioma in children and young adults. It aims to shrink the tumor or slow its growth, and to learn which patients benefit most and what side effects to expect.
This trial tests a new drug combination (tovorafenib and rituximab) for people with hairy cell leukemia (HCL) whose cancer has a specific genetic change called BRAF V600E. It looks at safety and how well the drugs work, both for people who have had treatment before and for those who have not.
This study tests an experimental medicine called tovorafenib for children and young adults (6 months to 25 years) with Japanese ancestry whose low-grade brain tumors have returned or grown after prior treatment. The medicine targets tumors with a specific BRAF genetic change.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This trial tests a combination of targeted therapy (dabrafenib or trametinib) with chemotherapy (clofarabine) for children with Langerhans cell histiocytosis (LCH) that is high-risk, has come back, or is not responding to other treatments. The goal is to see if this combination can help control the disease.
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
Hear when a new Recurrent Langerhans Cell Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.